Corrigendum to "Synthesis and SAR of novel capsazepine analogs with significant anti-cancer effects in multiple cancer types" [Bioorg. Med. Chem. 27 (1) (2019) 208-215].
作者信息
De La Chapa Jorge, Valdez Matthew, Ruiz Francisco, Gonzales Keith, Mitchell Wes, McHardy Stanton F, Hart Matthew J, Polusani Srikanth R, Gonzales Cara B
机构信息
Department of Comprehensive Dentistry, University of Texas Health Science Center at San Antonio School of Dentistry, San Antonio, TX 78229, USA.
Center for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, San Antonio, TX 78249, USA.
出版信息
Bioorg Med Chem. 2019 Jun 1;27(11):2280. doi: 10.1016/j.bmc.2019.04.007. Epub 2019 Apr 20.
PMID:31014563
Abstract
摘要
相似文献
1
Corrigendum to "Synthesis and SAR of novel capsazepine analogs with significant anti-cancer effects in multiple cancer types" [Bioorg. Med. Chem. 27 (1) (2019) 208-215].《新型辣椒素类似物的合成及其构效关系研究：对多种癌症类型具有显著抗癌作用》[《生物有机与药物化学》27 (1) (2019) 208 - 215]的勘误
Bioorg Med Chem. 2019 Jun 1;27(11):2280. doi: 10.1016/j.bmc.2019.04.007. Epub 2019 Apr 20.
2
Corrigendum to "Metal-assisted synthesis of unsymmetrical magnolol and honokiol analogs and their biological assessment as GABA receptor ligands" [Bioorg. Med. Chem. Lett. 25/2 (2015) 400-403].《“金属辅助合成不对称厚朴酚及和厚朴酚类似物及其作为GABA受体配体的生物学评估”的勘误》[《生物有机与药物化学快报》25/2 (2015) 400 - 403]
Bioorg Med Chem Lett. 2015 Apr 15;25(8):1811. doi: 10.1016/j.bmcl.2015.02.001. Epub 2015 Feb 20.
3
Corrigendum to "Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents" [Bioorg. Med. Chem. 19 (2011) 5409-5419].
Bioorg Med Chem. 2019 Sep 1;27(17):3960-3961. doi: 10.1016/j.bmc.2019.07.018. Epub 2019 Jul 22.
4
Commentary to "The structure of McN-5652" [Bioorg. Med. Chem. 9 (2001) 2105] and to the corrigendum to "The structure of McN-5652" [Bioorg. Med. Chem. 10 (2002) 3368].对《McN - 5652的结构》[《生物有机与药物化学》9 (2001) 2105]及《McN - 5652的结构》勘误[《生物有机与药物化学》10 (2002) 3368]的述评
Bioorg Med Chem. 2002 Oct;10(10):3367. doi: 10.1016/s0968-0896(02)00113-x.
5
Corrigendum to "Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184].《“M PAM临床前候选药物开发中的挑战：一系列氮杂环丁烷衍生的叔酰胺的发现、构效关系及生物学特性”的勘误》[《生物有机与药物化学快报》27(23) (2017) 5179 - 5184]
Bioorg Med Chem Lett. 2018 Sep 15;28(17):3014. doi: 10.1016/j.bmcl.2018.07.022. Epub 2018 Jul 31.
6
Corrigendum to 'Novel carbocyclic nucleoside analogs suppress glomerular mesangial cells proliferation and matrix protein accumulation through ROS-dependent mechanism in the diabetic milieu. II. Acylhydrazone-functionalized pyrimidines' [Bioorg. Med. Chem. Lett. 26 (2016) 1020-1024].
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2439. doi: 10.1016/j.bmcl.2019.06.039. Epub 2019 Jun 29.
7
Corrigendum to "Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity" [Bioorg. Med. Chem. 25 (2017) 1524-1532].
Bioorg Med Chem. 2017 Apr 15;25(8):2530. doi: 10.1016/j.bmc.2017.02.053. Epub 2017 Mar 10.
8
Corrigendum to "Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids" [Bioorg Med Chem Lett (2017) 4358-4369].
Bioorg Med Chem Lett. 2018 Feb 15;28(4):839. doi: 10.1016/j.bmcl.2018.01.024. Epub 2018 Jan 31.
9
Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].《“重新设计的三环抗癌剂”的勘误》[《生物有机与药物化学》23 (2015) 6528 - 6534]
Bioorg Med Chem. 2015 Dec 1;23(23):7487. doi: 10.1016/j.bmc.2015.11.002. Epub 2015 Nov 9.
10
Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].《新型苯甲酰胺衍生物作为高效的Smoothened拮抗剂的合成及生物学评价》的勘误[《生物有机与药物化学快报》24/5 (2014) 1426 - 1431]
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4558. doi: 10.1016/j.bmcl.2015.06.051. Epub 2016 Aug 16.
Zotero 插件